- Home
- SAFE vs ORIC Comparison
SAFE vs ORIC Comparison
Compare SAFE & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | ORIC |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SAFE | ORIC |
|---|---|---|
| Price | $13.43 | $11.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $19.56 | $18.78 |
| AVG Volume (30 Days) | 453.7K | ★ 1.2M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $398,968,000.00 | N/A |
| Revenue This Year | $0.84 | N/A |
| Revenue Next Year | $3.56 | N/A |
| P/E Ratio | $8.57 | ★ N/A |
| Revenue Growth | ★ 2.96 | N/A |
| 52 Week Low | $12.76 | $3.90 |
| 52 Week High | $21.90 | $14.93 |
Technical Indicators
Market Signals| Indicator | SAFE | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 40.42 |
| Support Level | $13.29 | $10.45 |
| Resistance Level | $13.75 | $12.14 |
| Average True Range (ATR) | 0.41 | 0.77 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 46.23 | 26.05 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.